Twist Bioscience Corporation $TWST Shares Purchased by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 65.2%, owning 265,649 shares after acquiring an additional 104,875 shares in the first quarter.
• Twist Bioscience has received a consensus rating of "Moderate Buy" from analysts with an average price target of $49.40.
• CFO Adam Laponis and CEO Emily M. Leproust recently sold shares of the company's stock, indicating insider selling activity amidst ongoing management transactions.

AQR Capital Management LLC increased its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 65.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 265,649 shares of the company's stock after purchasing an additional 104,875 shares during the quarter. AQR Capital Management LLC owned 0.44% of Twist Bioscience worth $10,429,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TWST. Stifel Financial Corp grew its position in Twist Bioscience by 19.6% in the 4th quarter. Stifel Financial Corp now owns 8,331 shares of the company's stock valued at $387,000 after acquiring an additional 1,364 shares in the last quarter. BNP Paribas Financial Markets grew its position in Twist Bioscience by 138.0% in the 4th quarter. BNP Paribas Financial Markets now owns 90,527 shares of the company's stock valued at $4,207,000 after acquiring an additional 52,495 shares in the last quarter. Cetera Investment Advisers acquired a new position in Twist Bioscience in the 4th quarter valued at about $220,000. Deutsche Bank AG grew its position in Twist Bioscience by 8.8% in the 4th quarter. Deutsche Bank AG now owns 159,752 shares of the company's stock valued at $7,424,000 after acquiring an additional 12,940 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in Twist Bioscience by 1,085.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 107,268 shares of the company's stock valued at $4,985,000 after acquiring an additional 98,223 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TWST shares. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer owned 103,569 shares in the company, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $25.76, for a total value of $58,346.40. Following the sale, the chief executive officer owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,911 shares of company stock valued at $288,159. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

Shares of TWST opened at $24.16 on Thursday. The stock has a 50-day simple moving average of $31.02 and a 200-day simple moving average of $34.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The stock has a market capitalization of $1.46 billion, a PE ratio of -16.66 and a beta of 2.31. Twist Bioscience Corporation has a 1 year low of $24.07 and a 1 year high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.